Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan

BACKGROUND AND AIM: Ustekinumab, a human anti‐interleukin‐12/23 monoclonal antibody, has been approved in Japan for the treatment of Crohn's disease. Here, we report the findings from an 8‐week interim analysis of post‐marketing surveillance to evaluate the safety and effectiveness of ustekinum...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Seiji, Asano, Teita, Nagano, Katsumasa, Tsuchiya, Hiroaki, Takagishi, Masayuki, Tsujioka, Shigeharu, Miura, Naomi, Matsumoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290907/
https://www.ncbi.nlm.nih.gov/pubmed/34180096
http://dx.doi.org/10.1111/jgh.15600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290907/
https://www.ncbi.nlm.nih.gov/pubmed/34180096
http://dx.doi.org/10.1111/jgh.15600

Ejemplares similares